 ENGLEWOOD, Colo., Sept. 21, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India DCGI of the Central Drugs Standard Control Organization CDSCO in the Phase II AP-019 clinical trial in India. 